Kyowa Kirin set to acquire ProStrakan for £292 million
This article was originally published in Scrip
Kyowa Hakko Kirin (KHK) has offered to pay 130 pence per share to acquire 100% of ProStrakan in an all-cash deal that values the UK firm at around £292 million.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.